Dexamethasone treatment of congenital adrenal hyperplasia in utero: An experimental therapy of unproven safety

Journal of Urology

Volumn 162, Issue 2, 1999, Pages 537-540

  Miller, Walter L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abnormalities; Adrenal hyperplasia, congenital; Hyperandrogenism

Indexed keywords

ANDROGEN; DEXAMETHASONE;

ANDROGEN RELEASE; ANDROGEN SYNTHESIS; CONFERENCE PAPER; CONGENITAL ADRENAL HYPERPLASIA; DRUG SAFETY; FEMALE; FETUS; FETUS MONITORING; HUMAN; MALE; PREGNANCY; PRENATAL DEVELOPMENT; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; STEROID 21 MONOOXYGENASE DEFICIENCY;

EID: 0032832404     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68624-7     Document Type: Conference Paper

References (54)

1. Therrell, B. L., Jr., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J. and Gunn, S.: Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics, 101: 583, 1998.
2. Miller, W. L. and Morel, Y.: The molecular genetics of 21-hydroxylase deficiency. Ann. Rev. Genet., 23: 371, 1989.
3. Morel, Y. and Miller, W. L.: Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv. Hum. Genet., 20: 1, 1991.
4. Mulaikal, R. M., Migeon, C. J. and Rock, J. A.: Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. New Engl. J. Med., 316: 178, 1987.
5. Kuhnle, U., Bullinger, M., Schwarz, H. P. and Knorr, D.: Partnership and sexuality in adult female patients with congenital adrenal hyperplasia. First results of a cross-sectional quality-of-life evaluation. J. Steroid Biochem. Mol. Biol., 45: 123, 1993.
6. Zucker, K. J., Bradley, S. J., Oliver, G., Blake, J., Fleming, S. and Hood, J.: Psychosexual development of women with congenital adrenal hyperplasia. Horm. Behav. 30: 300, 1996.
7. Meyer-Bahlburg, H. F., Gruen, R. S., New, M. I., Bell, J. J., Morishima, A., Shimshi, M., Bueno, Y., Vargas, I. and Baker, S. W.: Gender change from female to male in classical congenital adrenal hyperplasia. Horm. Behav. 30: 319, 1996.
8. Dittmann, R. W., Kappes, M. E. and Kappes, M. H.: Sexual behavior in adolescent and adult females with congenital adrenal hyperplasia. Psychoneuroendocrinology, 17: 153, 1992.
9. David, M. and Forest, M. G.: Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J. Pediatr., 105: 799, 1984.
10. Matteson, K. J., Phillips, J. A., III, Miller, W. L., Chung, B. C., Orlando, P. J., Frisch, H., Ferrandez, A. and Burr, I. M.: P450XXI (steroid 21-hydroxylase) gene deletions are not found in family studies of congenital adrenal hyperplasia. Proc. Natl. Acad. Sci. USA, 84: 5858, 1987.
11. White, P. C., Vitek, B., Dupont, B. and New, M. I.: Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. Proc. Natl. Acad. Sci. USA, 85: 4436, 1988.
12. Higashi, Y., Tanae, A., Inoue, H. and Fujii-Kuriyama, Y.: Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450(C21) gene: implications for steroid 21-hydroxylase deficiency. Am. J. Hum. Genet., 42: 17, 1988.
13. Morel, Y., Andre, J., Uring-Lambert, B., Hauptmann, G., Betuel, H., Tossi, M., Forest, M. G., David, M., Bertrand, J. and Miller, W. L.: Rearrangements and point mutations of P450c21 genes arc distinguished by five restriction endonuclease haplotypes identified by a new probing strategy in 57 families with congenital adrenal hyperplasia. J. Clin. Invest., 83: 527, 1989.
14. Chiou, S. H., Hu, M. C. and Chung, B. C.: A missense mutation of Ile172-Asn or Arg356-Trp causes steroid 21-hydroxylase deficiency. J. Biol. Chem., 256: 3549, 1990.
15. Tusie-Luna, M. T., Traktman, P. and White, P. C.: Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J. Biol. Chem., 265: 20916, 1990.
16. Helmburg, A., Tusie-Luna, M., Tabarelli, M., Kofler, R. and White, P. C.: R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions. Mol. Endocrinol., 6: 1318, 1992.
17. Speiser, P. W., Dupont, J., Zhu, D., Serrat, J., Buegeleisen, M., Tusie-Luna, M., Lesser, M., New, M. I. and White, P. C.: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Invest., 90: 584, 1992.
18. Wedell, A., Thilén, A., Ritzén, E. M., Stengler, B. and Luthman, H.: Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J. Clin. Endocrinol. Metab., 78: 1145, 1994.
19. Miller, W. L.: Clinical review 54: genetics, diagnosis, and management of 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab., 78: 241, 1994.
20. New, M. and White, P.: Genetic disorders of steroid hormone synthesis and metabolism. Baillieres Clin. Endocrinol. Metab., 9: 525, 1995.
21. Forest, M. G., David, M. and Morel, Y.: Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J. Steroid Biochem. Mol. Biol., 45: 75, 1993.
22. Speiser, P. W. and New, M. I.: Prenatal diagnosis and management of congenital adrenal hyperplasia. Clinics Perinatol., 21: 631, 1994.
23. Mercado, A. B., Wilson, R. C., Cheng, K. C., Wei, J. Q. and New, M. I.: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab., 80: 2014, 1995.
24. Lajic, S., Wedell, A., Bui, T.-H., Ritzen, E. and Holst, M.: Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab., 83: 3872, 1998.
25. Migeon, C. J.: Comments about the need for prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab., 70: 836, 1990.
26. Pang, S. Y. and Clark, A.: Newborn screening, prenatal diagnosis, and prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Trends Endocrinol. Metab., 1: 300, 1990.
27. Pang, S., Clark, A. T., Freeman, L. C., Dolan, L. M., Immken, L., Mueller, O. T., Stiff, D. and Shulman, D. I.: Maternal side-effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab., 75: 249, 1992.
28. Seckl, J. R. and Miller, W. L.: How safe is long-term prenatal glucocorticoid treatment? J.A.M.A., 277: 1077, 1997.
29. Miller, W. L.: Prenatal treatment of congenital adrenal hyperplasia - a promising experimental therapy of unproven safety. Trends Endocrinol. Metab., 9: 290, 1998.
30. Tapanainen, J., Kellokumpu-Lehtinen, P., Pelliniemi, L. and Huhtaniemi, I.: Age-related changes in endogenous steroids of human fetal testis during early and midpregnancy. J. Clin. Endocrinol. Metab., 52: 98, 1981.
31. White, P. C., Mune, T. and Agarwal, A. K.: 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrinol. Rev., 18: 135, 1997.
32. Rhoades, G. G., Jackson, L. G. and Schlesselman, S. E.: The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. New Engl. J. Med., 320: 609, 1989.
33. Kari, M. A., Raivio, K. O., Stenman, U.-H. and Voutilainen, R.: Serum cortisol, dehydroepiandrosterone sulfate, and sterol-binding globulins in preterm neonates: effects of gestational age and dexamethasone therapy. Pediatr. Res., 40: 319, 1996.
34. Miller, W. L.: Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Clinics Perinatol., 25: 799, 1998.
35. Forest, M. G., Bétuel, H. and David, M.: Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: update 88 of the French multicentric study. Endocrinol. Res., 15: 277, 1989.
36. Haan, E. A., Sergeantson, S. W., Norman, R., Rollond, A. K., Antonis, P., Richards, R. I. and Penfold, J. L.: Prenatal diagnosis and successful intrauterine treatment of a female fetus with 21-hydroxylase deficiency. Med. J. Aust., 156: 132, 1992.
37. Seckl, J. R.: Physiologic programming of the fetus. Clinics Perinatol., 25: 939, 1998.
38. Benirschke, K.: Adrenals in anencephaly and hydrocephaly. Obst. Gynec., 8: 412, 1956.
39. Allen, J. P., Greer, M. A., McGilvra, R., Castro, A. and Fisher, D. A.: Endocrine function in an anencephalic infant. J. Clin. Endocrinol. Metab., 38: 94, 1974.
40. Miyakawa, I., Ikeda, I. and Maeyama, M.: Transport of ACTH across human placenta. J. Clin. Endocrinol. Metab., 39: 440, 1974.
41. Osamura, R. Y.: Functional prenatal development of anencephalic and normal anterior pituitary glands. Acta Path. Jap., 27: 495, 1977.
42. Gray, E. S. and Abramovitch, D. R.: Morphologic features of the anencephalic adrenal gland in early pregnancy. Am. J. Obst. Gynec., 137: 491, 1980.
43. Goldman, A. S., Sharpior, B. H. and Katsumata, M.: Human foetal palatal corticoid receptors and teratogens for cleft palate. Nature, 272: 464, 1978.
44. Celsi, G., Kistner, A., Aizman, R., Eklöf, A.-C., Ceccatelli, S., de Santiago, A. and Jacobson, S. H.: Prenatal dexamethasone causes oligonephria, sodium retention, and higher blood pressure in the offspring. Pediatr. Res., 44: 317, 1998.
45. Uno, H., Lohmiller, L., Thieme, C., Kemnitz, J. W., Engle, M. J., Roeker, E. B. and Farrell, P. M.: Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macquues. I. Hippocampus. Dev. Brain Res., 53: 157, 1990.
46. Trautman, P. D., Meyer-Bahlburg, H. F. L., Postelnek, J. and New, M. I.: Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: results of a pilot study. Psychoneuroendocrinology, 20: 439, 1995.
47. Cooper, J., Hutson, J. and Warne, G.: Hydrometrocolpos following prenatal dexamethasone treatment for congenital adrenal hyperplasia (21-hydroxylase deficiency). Eur. J. Pediatr., 152: 9, 1993.
48. Benediktsson, R., Linday, R., Noble, J., Seckl, J. R. and Edwards, C. R. W.: Glucocorticoid exposure in utero: a new model for adult hypertension. Lancet, 341: 339, 1993.
49. Barker, D. J. P., Hales, C. H., Fall, C. H. D., Oxmond, C., Phipps, K. and Clarke, P. M. S.: Type 2 (non-insulin dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia, 36: 62, 1993.
50. Levine, R. S., Hennekens, C. H. and Jesse, M. J.: Blood pressure in prospective population based cohort of newborn and infant twins. Brit. Med. J., 308: 298, 1994.
51. Whincup, P. H., Cook, D., Papacosta, O. and Walker, M.: Birth weight and blood pressure: cross-sectional and longitudinal relations in childhood. Brit. Med. J., 311: 773, 1995.
52. Seeman, T. E., McEwen, B. S., Singer, B. H., Albert, M. S. and Rowe, J. W.: Increase in urinary cortisol excretion and memory declines: MacArthur studies on successful aging. J. Clin. Endocrinol. Metab., 82: 2458, 1997.
53. Kalmijn, S., Launer, L. J., Stolk, R. P., de Jong, F. H., Pols, H. A. P., Hofman, A., Breteler, M. M. B. and Lamberts, S. W. J.: A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J. Clin. Endocrinol. Metab., 83: 3487, 1998.
54. Wolkowitz, O. M.: Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology, 19: 233, 1994.